Longeveron (LGVN) Q2 2024 earnings summary

Executive summary

• Lomecel-B advanced in HLHS, Alzheimer's disease, and aging-related frailty, with HLHS and Alzheimer's as top priorities for 2024; aging-related frailty trial in Japan discontinued to focus resources.

• Achieved significant regulatory milestones, including FDA RMAT and Fast Track designations for Alzheimer's and multiple designations for HLHS.

• Completed Phase 2a CLEAR MIND trial in Alzheimer's, showing safety and efficacy; ELPIS II HLHS trial reached 70% enrollment, targeting completion by year-end 2024.

• Expanded contract manufacturing business, generating new revenue streams and leveraging underutilized GMP facility.

• Board strengthened with three new industry veterans to support strategic growth.

Financial highlights

• First-half 2024 revenue reached $1.0M, up 105% year-over-year, driven by increased Bahamas Registry Trial participation and new contract manufacturing revenue.

• Contract manufacturing contributed $0.2M in revenue for the first six months.

• Operating expenses declined 22% year-over-year, with G&A and R&D expenses both reduced by approximately $1.2M.

• Net loss for the first half of 2024 was $7.5M, down from $10.3M in the prior year period.

• Cash and cash equivalents stood at $12.4M as of June 30, 2024; subsequent capital raises and warrant exercises in July added $15.3M.

Outlook and guidance

• HLHS ELPIS II trial enrollment at 70%, targeting completion by year-end 2024; top-line data expected in Q1 2026.

• ELPIS I five-year follow-up data expected in Q3 2024.

• Planning FDA meetings for both HLHS and Alzheimer's programs before year-end to clarify regulatory paths.

• Contract manufacturing business expected to reach $4–$5M annual revenue within 1–2 years.

• Cash runway projected through Q4 2025, supported by recent financings.